Department of Pharmaceuticals Integrates ‘Pharma Sahi Daam’ and ‘Pharma Jan Samadhan’ into a Single Unified Platform

Date:

Share post:

​The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, has officially integrated two essential citizen services, the Pharma Sahi Daam price-finding tool and the Pharma Jan Samadhan grievance redressal system into a single, unified digital platform. 

Developed in collaboration with the National Pharmaceutical Pricing Authority (NPPA), the integrated portal offers a seamless, one-stop solution for consumers seeking real-time access to official medicine pricing information and structured complaint resolution mechanisms.

​Through the consolidated platform, patients, consumers, and healthcare providers can instantly look up authorized ceiling prices and maximum retail prices (MRPs) for both scheduled and non-scheduled medicines. 

Concurrently, users can directly report, register, and track price-related violations, shortages, or distribution discrepancies on the same interface. By bridging information discovery and enforcement, the initiative strengthens consumer protection, promotes market transparency, and ensures fair access to essential medications across the nation.

Written by: Pragna Biswas

Graphics by: Pramit Hazra

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related articles

Sun Pharma Among Nine Drugmakers Joining Trump Administration’s Most-Favoured-Nation Pricing Pact

The Trump administration has widened its most-favored-nation (MFN) drug pricing programme by signing nine fresh manufacturers into the...

Pradhan Mantri Bhartiya Janaushadhi Pariyojana Records ₹2,252.19 Crore in Sales for FY 2025–26, Saving Citizens ₹9,000 Crore

The Department of Pharmaceuticals announced that the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) achieved total sales of ₹2,252.19 crore in the financial year...

Cipla Partners with SBP Group for Next-Gen HER2 Cancer Therapy

Cipla Limited and Sino Biopharmaceutical Limited (SBP Group) announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ),...

Eli Lilly to Acquire Merida Biosciences in $2.875B Deal to Advance Precision Immunology

Eli Lilly and Company has entered into a definitive agreement to acquire Merida Biosciences, Inc., a privately held...